OKYO Pharma to Showcase Urcosimod at Key European Ophthalmology Forums
TipRanks (Wed, 9-Sep 7:28 AM ET)
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026
Globe Newswire (Wed, 9-Sep 7:00 AM ET)
OKYO Pharma to Highlight Urcosimod Progress at Cantor Global Healthcare Conference
TipRanks (Tue, 8-Sep 7:28 AM ET)
OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference
Globe Newswire (Tue, 8-Sep 7:00 AM ET)
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
Globe Newswire (Tue, 28-Jul 7:00 AM ET)
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
Globe Newswire (Mon, 27-Jul 7:00 AM ET)
OKYO Pharma Announces Purchase of Shares by Director
Globe Newswire (Thu, 23-Jul 12:00 PM ET)
OKYO Pharma Announces Purchase of Shares by Chief Executive Officer
Globe Newswire (Thu, 23-Jul 7:00 AM ET)
OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director
Globe Newswire (Wed, 22-Jul 10:00 AM ET)
OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
Globe Newswire (Wed, 22-Jul 7:00 AM ET)
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.
Okyo Pharma Limited - trades on the NASDAQ stock market under the symbol OKYO.
As of September 10, 2026, OKYO stock price declined to $1.43 with 145,493 million shares trading.
OKYO has a beta of 1.09, meaning it tends to be more sensitive to market movements. OKYO has a correlation of 0.05 to the broad based SPY ETF.
OKYO has a market cap of $75.05 million. This is considered a Micro Cap stock.
In the last 3 years, OKYO traded as high as $3.35 and as low as $.81.
OKYO has underperformed the market in the last year with a price return of -34.4% while the SPY ETF gained +17.3%. OKYO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -4.0% and -7.7%, respectively, while the SPY returned +4.7% and -1.7%, respectively.
OKYO support price is $1.38 and resistance is $1.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OKYO shares will trade within this expected range on the day.